Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
Drug Toxicity: Risk factors01:24

Drug Toxicity: Risk factors

Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Diffuse pediatric-type high-grade glioma, H3-wildtype and IDH-wildtype, of the adult cerebellum: a report of 2 cases.

Brain tumor pathology·2026
Same author

Arterial Supply to the Free Edge of the Tentorium.

Journal of neuroendovascular therapy·2026
Same author

Soy lysolecithin attenuates hypertension and behavioral impairments in mice fed a high-salt diet through receptor-specific regulation of prostaglandin signaling and arachidonic acid-derived prostaglandin production.

Neurochemistry international·2026
Same author

Nationwide genomic data analysis of central nervous system tumors in Japan based on C-CAT database.

International journal of clinical oncology·2026
Same author

Comparing artificial intelligence and physician performance in predicting IDH mutation status in glioma.

NPJ digital medicine·2026
Same author

Durable tumor control with stereotactic radiotherapy and doxorubucin-ifosfamide chemotherapy in primary intracranial sarcoma, <i>DICER1</i>-mutant: a case report.

International cancer conference journal·2026

Related Experiment Video

Updated: Jul 6, 2026

Anteromesial Temporal Lobectomy for Medically Intractable Temporal Lobe Epilepsy: An Operative Study
11:29

Anteromesial Temporal Lobectomy for Medically Intractable Temporal Lobe Epilepsy: An Operative Study

Published on: August 15, 2025

[Temozolomide: Temodal].

Nobusada Shinoura1, Ryoji Yamada, Yusuke Tabei

  • 1Dept. of Neurosurgery, Komagome Metropolitan Hospital, Japan.

Gan to Kagaku Ryoho. Cancer & Chemotherapy
|March 19, 2008
PubMed
Summary

Temozolomide (TMZ) is a key oral chemotherapy drug that improves survival in glioblastoma (GBM) when combined with radiotherapy. It shows efficacy across various brain tumors, with specific molecular markers predicting patient response.

More Related Videos

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
05:29

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Published on: March 28, 2021

Related Experiment Videos

Last Updated: Jul 6, 2026

Anteromesial Temporal Lobectomy for Medically Intractable Temporal Lobe Epilepsy: An Operative Study
11:29

Anteromesial Temporal Lobectomy for Medically Intractable Temporal Lobe Epilepsy: An Operative Study

Published on: August 15, 2025

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
05:29

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Published on: March 28, 2021

Area of Science:

  • Oncology
  • Pharmacology
  • Neuro-oncology

Background:

  • Temozolomide (TMZ) is an oral alkylating agent.
  • It is the only anticancer drug proven in Phase III trials to enhance survival in glioblastoma (GBM) when given with radiotherapy.
  • TMZ achieves significant concentrations in brain tumors and cerebrospinal fluid.

Purpose of the Study:

  • To summarize the efficacy and safety of TMZ in brain tumor treatment.
  • To discuss molecular markers predicting response to TMZ.
  • To review ongoing and future studies of TMZ in combination therapies.

Main Methods:

  • Review of pharmacokinetic studies.
  • Analysis of clinical trial data for various brain tumors.
  • Identification of molecular markers like MGMT promoter methylation and 1p/19q deletion.

Main Results:

  • TMZ improves survival in glioblastoma (GBM) with radiotherapy.
  • Effective for gliomas, primary CNS lymphoma, melanoma, and neuroblastoma.
  • MGMT promoter methylation (GBM) and 1p/19q deletion (gliomas) predict favorable response.

Conclusions:

  • TMZ is a vital treatment for brain tumors, particularly GBM.
  • Careful patient selection based on molecular markers optimizes outcomes.
  • Management of side effects like myelosuppression and nausea is crucial.